Open AccessEffect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
Author(s) -
Anne C. Goldberg,
Lawrence A. Leiter,
Erik S.G. Stroes,
Seth J. Baum,
Jeffrey C. Hanselman,
LeAnne T. Bloedon,
Narendra D. Lalwani,
Pragna Patel,
Xin Zhao,
P. Barton Duell
Publication year - 2019
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2019.16585
Subject(s) - medicine , placebo , randomization , gastroenterology , cholesterol , clinical endpoint , randomized controlled trial , lipoprotein , familial hypercholesterolemia , lipid profile , endocrinology , pathology , alternative medicine
Additional treatment options are needed for patients who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lipid-lowering therapies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom